<DOC>
	<DOCNO>NCT00022321</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody gemtuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Randomized phase II trial study effectiveness gemtuzumab treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Gemtuzumab Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine total survival patient intermediate-2 high-risk myelodysplastic syndrome treat gemtuzumab ozogamicin . II . Assess quality life patient treated drug . III . Compare two different dose schedule drug patient . IV . Determine safety drug patient . V. Determine number patient treated drug achieve complete remission , partial remission , stable disease , major minor hematologic improvement , major minor cytogenetic response . VI . Determine progression-free survival , relapse-free survival , time progression acute myeloid leukemia patient treat drug . VII . Determine number transfusion , number day IV antibiotic , number day hospitalize patient treated drug . VIII . Determine possible predictor response patient treated drug , include age , karyotype , multi-drug resistance efflux . IX . Determine pharmacokinetics drug patient . X. Correlate result pharmacogenomic study gene activation response therapy patient treat drug . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord age ( 60 vs 60 ) IPSS score ( 1.5-2.0 v 2.5 great ) . Patients randomize one two treatment arm . Arm I : Patients receive gemtuzumab ozogamicin IV 2 hour day 1 . Arm II : Patients receive gemtuzumab ozogamicin IV 2 hour day 1 15 . After completion induction therapy , patient arm stable respond disease may receive post-remission therapy comprise 3 additional dos gemtuzumab ozogamicin approximately 28-42 day apart . Quality life assess baseline , day 29 arm I , day 43 arm II , day 127 patient receive additional dos study drug , 8 month patient . Patients respond induction therapy follow monthly 8 month every 3 month thereafter . Patients receive post-remission therapy follow every 3 month . PROJECTED ACCRUAL : Approximately 128 patient ( 64 per treatment arm ) accrue study within 12 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm myelodysplastic syndrome ( MDS ) Refractory anemia ( RA ) RA ring sideroblast RA excessive blast ( RAEB ) RAEB transformation ( stable disease least 2 month ) No chromosomal abnormality include ( 8 ; 21 ) , inv ( 16 ) , ( 15 ; 17 ) No chronic myelomonocytic leukemia proliferative type ( WBC great 12,000/mm3 ) No know CNS involvement MDS blast progression International Prognostic Scoring System ( IPSS ) score least 1.5 PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 2.0 mg/dL Cardiovascular : No severe cardiac disease Pulmonary : No severe pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 year study HIV negative No prior active malignancy except basal cell squamous cell skin cancer No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : No prior stem cell transplantation No prior antiCD33 antibody At least 4 week since prior hematopoietic growth factor , epoetin alfa , cytokine therapy Chemotherapy : No prior chemotherapy MDS malignancy No concurrent cytotoxic chemotherapy Endocrine therapy : At least 4 week since prior systemic steroid except topical inhaled steroid No concurrent systemic steroid except topical inhaled steroid Radiotherapy : No prior radiotherapy MDS malignancy Surgery : No prior organ transplantation Other : At least 4 week since prior immunosuppressive therapy At least 4 week since prior investigational agent No concurrent immunosuppressive therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
</DOC>